Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

NCT00710710 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: BI 2536

Sponsor

Boehringer Ingelheim